Marina Serper1,2,3, David E Kaplan1,2, Justine Shults4, Peter P Reese3,4,5, Lauren A Beste6,7,8, Tamar H Taddei9,10, Rachel M Werner1,3,11. 1. Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA. 2. Division of Gastroenterology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 3. Leonard Davis Institute of Health Economics, Philadelphia, PA. 4. Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA. 5. Renal-Electrolyte and Hypertension Division, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 6. Health Services Research and Development, Seattle, WA. 7. General Medicine Service, VA Puget Sound Health Care System, Seattle, WA. 8. Division of General Internal Medicine, University of Washington, Seattle, WA. 9. VA Connecticut Healthcare System, West Haven, CT. 10. Division of Gastroenterology, Yale University School of Medicine, New Haven, CT. 11. Division of General Internal Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Abstract
Decompensated cirrhosis is associated with high morbidity and mortality. However, no standardized quality measures (QMs) have yet been adopted widely. The Veterans Affairs (VA) Advanced Liver Disease Technical Advisory Group recently developed a set of six internal QMs to guide quality improvement efforts in cirrhosis in the domains of access to care, hepatocellular carcinoma surveillance, variceal surveillance, quality of inpatient care for upper gastrointestinal bleeding, and cirrhosis-related rehospitalizations. We aimed to (1) quantify adherence to cirrhosis QMs and (2) determine whether adherence was associated with all-cause mortality and health care use within a large national cohort of veterans with cirrhosis. We performed a retrospective study using data from the Veterans Outcomes and Costs Asociated with Liver Disease cohort of 121,129 patients newly diagnosed with cirrhosis from January 1, 2008, to December 31, 2016, at 128 VA facilities. The mean follow-up time was 2.7 years (interquartile range, 1.1-5.1 years). Adherence to outpatient access to specialty care was 71%, variceal surveillance was 32%, and early postdischarge care was 54%. In adjusted analyses, outpatient access to specialty care (hazard ratio [HR], 0.80; 95% confidence interval [CI], 0.78-0.82), hepatocellular carcinoma surveillance (HR, 0.92; 95% CI, 0.90-0.95), variceal surveillance (HR, 0.93; 95% CI, 0.89-0.99), and early postdischarge care (HR, 0.57; 95% CI, 0.54-0.60) were associated with lower all-cause mortality. Readmissions after 30 days (HR, 1.53; 1.46-1.60) and 90 days (HR, 1.88; 95% CI, 1.54-1.70) were associated with higher all-cause mortality. Higher adherence to QMs was also associated with lower inpatient health care use. Conclusion: Five of the six proposed VA cirrhosis QMs were measurable using existing data sources, associated with mortality and health care use, and may be used to guide future quality improvement efforts in cirrhosis.
Decompensated cirrhosis is associated with high morbidity and mortality. However, no standardized quality measures (QMs) have yet been adopted widely. The Veterans Affairs (VA) Advanced Liver Disease Technical Advisory Group recently developed a set of six internal QMs to guide quality improvement efforts in cirrhosis in the domains of access to care, hepatocellular carcinoma surveillance, variceal surveillance, quality of inpatient care for upper gastrointestinal bleeding, and cirrhosis-related rehospitalizations. We aimed to (1) quantify adherence to cirrhosis QMs and (2) determine whether adherence was associated with all-cause mortality and health care use within a large national cohort of veterans with cirrhosis. We performed a retrospective study using data from the Veterans Outcomes and Costs Asociated with Liver Disease cohort of 121,129 patients newly diagnosed with cirrhosis from January 1, 2008, to December 31, 2016, at 128 VA facilities. The mean follow-up time was 2.7 years (interquartile range, 1.1-5.1 years). Adherence to outpatient access to specialty care was 71%, variceal surveillance was 32%, and early postdischarge care was 54%. In adjusted analyses, outpatient access to specialty care (hazard ratio [HR], 0.80; 95% confidence interval [CI], 0.78-0.82), hepatocellular carcinoma surveillance (HR, 0.92; 95% CI, 0.90-0.95), variceal surveillance (HR, 0.93; 95% CI, 0.89-0.99), and early postdischarge care (HR, 0.57; 95% CI, 0.54-0.60) were associated with lower all-cause mortality. Readmissions after 30 days (HR, 1.53; 1.46-1.60) and 90 days (HR, 1.88; 95% CI, 1.54-1.70) were associated with higher all-cause mortality. Higher adherence to QMs was also associated with lower inpatient health care use. Conclusion: Five of the six proposed VA cirrhosis QMs were measurable using existing data sources, associated with mortality and health care use, and may be used to guide future quality improvement efforts in cirrhosis.
Authors: Paula M Buchanan; Jennifer R Kramer; Hashem B El-Serag; Steven M Asch; Youssef Assioun; Bruce R Bacon; Fasiha Kanwal Journal: Am J Gastroenterol Date: 2014-07 Impact factor: 10.864
Authors: Jessica L Mellinger; Caroline R Richardson; Amit K Mathur; Michael L Volk Journal: Clin Gastroenterol Hepatol Date: 2014-09-28 Impact factor: 11.382
Authors: P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim Journal: Hepatology Date: 2001-02 Impact factor: 17.425
Authors: Lauren A Beste; Steven L Leipertz; Pamela K Green; Jason A Dominitz; David Ross; George N Ioannou Journal: Gastroenterology Date: 2015-08-05 Impact factor: 22.682
Authors: Marina Serper; Ethan M Weinberg; Jordana B Cohen; Peter P Reese; Tamar H Taddei; David E Kaplan Journal: Hepatology Date: 2020-11-09 Impact factor: 17.425
Authors: Elizabeth S Aby; Adam C Winters; Jonathan Lin; Aileen Bui; Jenna Kawamoto; Matthew B Goetz; Debika Bhattacharya; Joseph R Pisegna; Folasade P May; Arpan A Patel; Jihane N Benhammou Journal: Hepatol Commun Date: 2020-04-24
Authors: Marina Serper; Allen W Cubell; Mary Elisabeth Deleener; Tara K Casher; Dale J Rosenberg; Dale Whitebloom; Roy M Rosin Journal: Hepatology Date: 2020-08 Impact factor: 17.425
Authors: Nadim Mahmud; Sumeet K Asrani; David E Kaplan; Gerald O Ogola; Tamar H Taddei; Patrick S Kamath; Marina Serper Journal: Liver Transpl Date: 2020-12-09 Impact factor: 5.799